Construction and production of an IgG-like tetravalent bispecific antibody, IgG-single-chain Fv fusion

Methods in Molecular Biology

Volumn 1060, Issue , 2014, Pages 185-213

  Lu, Dan ^a   Zhu, Zhenping ^a  

^a Kadmon Corporation   (United States)

Author keywords

Antibody engineering; Antibody production; Bispecific antibody; Cancer therapy; Recombinant antibody; Single chain variable fragment (scFv)

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; CANCER GROWTH FACTOR; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN G; RECOMBINANT ANTIBODY; TOXIN;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CONJUGATION; EFFECTOR CELL; EXPRESSION VECTOR; HYBRID; PRIORITY JOURNAL; PURIFICATION; CELLS; HYBRIDOMA; MOLECULE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84931267142     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-586-6_11     Document Type: Article

References (29)

1. Fischer N, Leger O (2007) Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 74:3-1
2. Jain M, Kamal N, Batra SK (2007) Engineering antibodies for clinical applications. Trends Biotechnol 25:307-3
3. Demarest SJ, Glaser SM (2008) Antibody therapeutics, anti-body engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 11:675-6
4. Chames P, Baty D (2009) Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 12:276-2
5. Thakur A, Lum LG (2010) Cancer therapy with bispecific antibodies: clinical experience. Curr Opin Mol Ther 12:340-3
6. Kipriyanov SM, Le Gall F (2004) Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Devel 7:233-2
7. Lum LG, Thakur A (2011) Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs 25:365-3
8. Shen J, Zhu Z (2008) Catumaxomab, a rat/murine hybrid trifunctional bispecific mono- clonal antibody for the treatment of cancer. Curr Opin Mol Ther 10:373-3
9. Marvin JS, Zhu Z (2006) Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Curr Opin Drug Discov Devel 9:184-193
10. Lu D, Zhang H, Koo H et al (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280:19665-19672
11. Wu C, Ying H, Grinnell C et al (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25:1290-1297
12. Schaeter G, Haber L, Crocker L et al (2011) A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20:472-486
13. Michaelson JS, Demarest SJ, Miller B et al (2009) Anti-tumor activity of stabilityengineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 1:128-141
14. Dong J, Sereno A, Aivazian D et al (2011) A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 3:273-288
15. Baeuerle P (2012) Revival of bispecific antibodies, resource of 3rd annual world bispecific antibody summit (Boston, USA). http://bispecific.com/ uploads/ffiles/2012/05/904821.pdf
16. Marvin JS, Zhu Z (2005) Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26:649-658
17. Dong J, Sereno A, Snyder WB et al (2011) Stable IgG-like bispecific antibodies directed towards the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 286:4703-4717
18. de Haard HJ, van Neer N, Reurs A et al (1999) A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 274:18218-18230
19. Hoet RM, Cohen EH, Kent RB et al (2005) Generation of high-affinity human antibodies by combing donor-derived and synthetic complementarity- determining-region diversity. Nat Biotechnol 23:344-348
20. Lu D, Shen J, Vil MD et al (2003) Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 278:43496-43507
21. Reiter Y, Brinkmann U, Lee B et al (1996) Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol 14:1239-1245
22. Worn A, Pluckthun A (2001) Stability engineering of scfv fragments. J Mol Biol 305:989-1010
23. Miller BR, Demarest SJ, Lugovskoy A et al (2010) Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 23:549-557
24. Demarest SJ, Glaser SM (2008) Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 11:675-687
25. Mabry R, Lewis KE, Moore M et al (2010) Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 23:115-127
26. Mabry R, Snavely M (2010) Therapeutic bispecific antibodies: the selection of stable single-chain fragments to overcome engineering obstacles. IDrugs 13:543-549
27. Lu D, Jimenez X, Witte L, Zhu Z (2004) The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun 28:507-513
28. Orcutt KD, Ackerman ME, Cieslewicz M et al (2009) A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 23:221-228
29. Dimasi N, Gao C, Fleming R et al (2009) The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 393:672-692